Intensity Therapeutics Q3 Net Loss Widens on Higher R&D Costs
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…
Story updates
01:03:33 PM UTC
SquawkNews
Intensity Therapeutics reported a third-quarter 2026 net loss of $3.5 million, compared with $2.7 million a year earlier, and had $8.5 million in cash and cash equivalents at September 30. The company resumed enrollment activities in its Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 studies during…
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…